Assessment of variability and normalization methods using the plasma 7K SomaScan® Assay v4.1
Assessment of variability and normalization methods using the plasma 7K SomaScan Assay v4.1
The 7K SomaScan Assay v4.1 is capable of measuring 7,288 human proteins. In this webinar, the speakers present the largest technical assessment of this platform to date based on a study of 2,050 samples across 22 plates.(1) Included in the study design were inter-plate technical duplicates from 102 human subjects, which allowed them to characterize different normalization procedures, evaluate assay variability by multiple analytical approaches, present signal-over-background metrics, and discuss potential specificity issues.
By providing detailed performance assessments on this wide range of technical aspects, the presenters aim for this work to serve as a valuable resource for the growing community of SomaScan users.
Topics covered:
- A comparative analysis of different normalization strategies
- An analysis of performance across 7,288 SOMAmers® Reagents targeting human proteins
- A discussion of sensitivity and specificity of the assay
Julián Candia, PhD
Staff Scientist
Longitudinal Studies Section
Translational Gerontology Branch
National Institute on Aging
National Institutes of Health
Keenan Walker, PhD
Investigator, National Institute on Aging Intramural Research Program
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND) unit
Assessment of variability and normalization methods using the plasma 7K SomaScan Assay v4.1
A presentation by Julián Candia, PhD, and Keenan Walker, PhD
References
- Candia J, Daya GN, Tanaka T, Ferrucci L, Walker KA. Assessment of variability in the plasma 7k SomaScan proteomics assay. Sci Rep. 2022 Oct 13;12(1):17147. doi: 10.1038/s41598-022-22116-0. PMID: 36229504; PMCID: PMC9561184.
More webinars
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.